Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TOTUM-854 is a **polyphenol-rich blend of six plant extracts** developed as a proprietary botanical formulation for vascular protection and the prevention or management of mild to moderate hypertension. It is not a single chemical entity but a standardised combination whose individual plant-derived compounds have been shown to impact inflammation and oxidative stress. Its mechanism of action includes: - Inhibition of angiotensin-converting enzyme 1 (ACE-1) activity, which reduces the production of angiotensin II and thus lowers vasoconstriction and blood pressure. - Reduction of oxidative stress by lowering NADPH oxidase (NOX2) mediated reactive oxygen species (ROS) production. - Reduction of inflammatory markers (IL-1β, MCP-1, and VCAM-1), which are implicated in endothelial dysfunction. TOTUM-854 shows bioactive metabolite absorption in humans and has demonstrated efficacy in rodent models and ex vivo human vascular assays. Its development is ongoing through clinical trials for **moderate hypertension** and potentially as a preventive strategy against cardiovascular disease. The developer is Valbiotis, a French nutraceutical company.[1][2][3][4][5]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on TOTUM-854.